Trials / Terminated
TerminatedNCT01246752
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- University Hospital Carl Gustav Carus · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human Stem Cell Transplantation | Human allogenic stem cells |
| DRUG | Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC) | Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5 |
Timeline
- Start date
- 2011-02-10
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
- First posted
- 2010-11-23
- Last updated
- 2021-10-29
Locations
19 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01246752. Inclusion in this directory is not an endorsement.